MAP2K7 and melanoma: In 2020, the first triple-therapy combining BRAF/MEK targeted and anti-PD-1 immunotherapy with atezolizumab, vemurafenib and cobimetinib was approved for unresectable or metastatic BRAF V600-mutated melanoma (IMspire150 study), while another trial investigating triple therapy missed its endpoint.